By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Triptan (migraine) > Sumatriptan

Sumatriptan

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
6 Min Read
SHARE
4 min read|715 words

Sumatriptan: A Comprehensive Drug Profile

What is Sumatriptan?

Sumatriptan is a prescription medication belonging to a class of drugs called triptans, specifically designed to treat migraine headaches and cluster headaches. It works by targeting specific serotonin receptors in the brain and blood vessels to provide rapid relief from severe headache pain. Sumatriptan is available in multiple formulations including tablets, nasal spray, and injectable forms for varying degrees of migraine severity.

Uses

Sumatriptan is approved for several specific headache conditions:

Acute migraine treatment: The primary use is for treating moderate to severe migraine attacks in adults, providing relief from headache pain and associated symptoms like nausea and light sensitivity.

Cluster headache treatment: Particularly effective for acute cluster headache episodes, with the injectable form often preferred for rapid onset of action.

Submit Your Paper
GMJ_Submit_Banner

Migraine with aura: Can be used to treat migraines that occur with visual or sensory disturbances, though it’s most effective when taken after the aura phase.

Status migrainosus: May be used as part of treatment for prolonged migraine attacks lasting more than 72 hours, often in emergency department settings.

Hemiplegic migraine: In some cases, may be prescribed for certain types of complicated migraines, though this requires careful medical supervision.

How it works

Sumatriptan functions as a selective serotonin receptor agonist, specifically targeting 5-HT1B and 5-HT1D receptors in blood vessels and nerve endings. When activated, these receptors cause constriction of dilated cranial blood vessels and block the release of inflammatory substances that contribute to migraine pain. This dual action helps reverse the vascular changes and neurochemical imbalances that occur during migraine attacks.

Side effects

Common side effects include:

  • Injection site reactions (pain, redness, swelling)
  • Tingling or numbness in fingers and toes
  • Dizziness and drowsiness
  • Muscle weakness or fatigue
  • Nausea and vomiting
  • Flushing or feeling of warmth
  • Dry mouth
  • Temporary increase in blood pressure

Serious side effects requiring immediate medical attention:

  • Chest pain, tightness, or pressure
  • Severe allergic reactions with difficulty breathing
  • Signs of stroke (sudden weakness, speech problems, vision changes)
  • Severe abdominal pain or bloody diarrhea
  • Seizures or severe changes in mental state

Warnings and precautions

Cardiovascular contraindications: Sumatriptan should not be used by patients with coronary artery disease, uncontrolled high blood pressure, or history of heart attack or stroke due to its vessel-constricting effects.

Pregnancy considerations: Classified as FDA Pregnancy Category C, meaning it should only be used during pregnancy if potential benefits justify potential risks to the fetus.

Liver function: Patients with severe liver impairment may require dose adjustments or alternative treatments, as the medication is metabolized primarily by the liver.

Age restrictions: Not recommended for patients over 65 years of age or under 18 years due to increased risk of cardiovascular complications and limited safety data respectively.

Overuse potential: Frequent use (more than 10 days per month) can lead to medication overuse headaches and should be avoided.

Interactions

MAO inhibitors: Can significantly increase sumatriptan levels, requiring at least 2 weeks between discontinuing MAOIs and starting sumatriptan.

Other triptans: Should not be used within 24 hours of other triptan medications due to additive vasoconstrictor effects.

Ergot alkaloids: Concurrent use with ergotamine or dihydroergotamine increases risk of severe vasoconstriction and should be avoided.

SSRIs and SNRIs: May increase risk of serotonin syndrome, particularly with medications like fluoxetine, paroxetine, and venlafaxine.

St. John’s Wort: This herbal supplement can increase serotonin activity and potentially lead to serotonin syndrome when combined with sumatriptan.

Propranolol: Can increase sumatriptan blood levels, potentially requiring dose adjustments.

Topiramate: May alter sumatriptan metabolism, though clinical significance is generally minimal.

Check interactions with the GMJ Interaction Checker

Dosage

Oral tablets: Typical starting dose is 25-50 mg, with a maximum single dose of 100 mg. If headache returns, a second dose may be taken after 2 hours, with maximum daily dose of 200 mg.

Subcutaneous injection: Standard dose is 6 mg, which may be repeated once after 1 hour if needed, with maximum daily dose of 12 mg.

Nasal spray: Usually 5-20 mg in one nostril, may repeat once after 2 hours if necessary, with maximum daily dose of 40 mg.

Dosage should always be individualized and determined by a healthcare provider based on patient response, medical history, and severity of symptoms.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Sumatriptan." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/sumatriptan/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Why Women Choose Freebirth: What Research Reveals About Unattended Childbirth

A growing number of women are choosing unattended childbirth, driven by desire…

The Optimal Height for Elite Soccer Players: What Sports Science Reveals

Elite soccer demonstrates position-specific height selection rather than universal stature advantage. Analysis…

International Survey Reveals Critical Gaps in Cardio-Oncology Training Despite Rising Clinical Demand

An international survey presented at ESC Cardio-Oncology 2026 has identified substantial deficiencies…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Rizatriptan

By
Prof. Giorgi Pkhakadze
02/06/2026

Zolmitriptan

By
Prof. Giorgi Pkhakadze
02/06/2026

Eletriptan

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up